Superworth

Ernexa Therapeutics price to sales ratio ERNA

Market value divided by revenue over the last twelve months, since 2013.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
12.1×
Aug 2025
10-year median
0.6×
10-year range
0.2× to 137×
Peer median
1.4×

Ernexa Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Aug 2025, at 12.1×.

On the days it had one over the last ten years, its median was 0.6×, from 0.2× in Apr 2020 to 137× in Jun 2021.

Price to sales ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202512.1×11.1×48.6×
202421.8×21.5×71.7×
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
202179.7×0.7×137×
20200.7×0.2×0.7×
20190.3×0.2×0.5×
20180.3×0.3×0.8×
20170.5×0.5×0.9×
20160.8×0.4×1.0×
20150.6×0.5×1.9×
20141.6×1.2×2.3×
20131.8×1.8×2.4×

Against its peers

Companies in Healthcare nearest Ernexa Therapeutics' size, closest first, today.

CompanyPrice to sales ratio
ERNAErnexa Therapeuticsn/m
OXBROXBRIDGE RE HOLDINGS2.8×
EDUCEducational Development0.4×
GTIMGood Times Restaurants0.1×
MDRRMedalist Diversified1.6×
BCGBinah Capital0.1×
VIPVulcan Infrastructure & Power0.4×
MXCMexco Energy3.0×
CKXCKX Lands31.0×
MSGMMotorsport Games1.5×
ATCHAtlasClear1.2×
Peer median1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Ernexa Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.